eRapa

Phase 3Small molecule

RRapamycin Holdings, Inc. dba Emtora Biosciences

eRapa is one of 8 small molecule programs targeting Familial adenomatous polyposis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Familial Adenomatous PolyposisRecruiting

Familial Adenomatous PolyposisPhase 3

Recruiting

Competition

Competitive Landscape

8 competitors in Familial Adenomatous Polyposis

#DrugCompanyPhaseTrials

Actigall

Rocaltrol

Bayer Aspirin

E-Mycin

AAzurity Pharmaceuticals

Approved

2 5

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 6

Rapamycin

MMaastricht Radiation Oncology

Phase 2

1 7

eRapa

RRapamycin Holdings, Inc. dba Emtora Biosciences

Phase 3

1 8

REC-4881

RRecursion Pharmaceuticals Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

Phase 3Recruiting

Familial Adenomatous Polyposis

NCT06950385

Clinical

Trials by Indication[1]

Bladder Cancer1 trial

Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention

Recruiting·RRobert Svatek·Phase 2·NCT04375813·166 enrolled

Familial adenomatous polyposis1 trial

Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

Recruiting·RRapamycin Holdings Inc.·Phase 3·NCT06950385·168 enrolled

Prostate Cancer1 trial

Trial of eRapa in Prostate Cancer Patients

Completed·RRapamycin Holdings, Inc. dba Emtora Biosciences·Phase 1·NCT03618355·15 enrolled

Familial Adenomatous Polyposis (FAP)1 trial

Expanded Access Program for 0.5 mg eRapa in Familial Adenomatous Polyposis

Available·BBiodexa Pharmaceuticals··NCT07689942

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for eRapa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — eRapa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for eRapa. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Rapamycin Holdings, Inc. dba Emtora Biosciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: RRapamycin Holdings, Inc. dba Emtora Biosciences

eRapa

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2031

Trials by Indication[1]

Bladder Cancer1 trial

Familial adenomatous polyposis1 trial

Prostate Cancer1 trial

Familial Adenomatous Polyposis (FAP)1 trial

References

Drug Info

Quick Facts

Related News